Expert network works towards better drug development for children
IMI project c4c has pioneered an advice process involving diverse experts including patients to aid drug developers when designing paediatric clinical trials.
IMI project c4c has pioneered an advice process involving diverse experts including patients to aid drug developers when designing paediatric clinical trials.
Today’s spotlight is on Jaana Kallio from the Helsinki University Hospital. You will be surprised in how many parallel activities Jaana is involved, from helping researchers with paperwork to preparing the future of c4c!
Kawasaki disease (KD) is an acute self-limiting inflammatory vasculitis affecting predominantly medium-sized arteries, particularly the coronary arteries. A number of recent studies conducted in different European countries have demonstrated alarmingly high coronary complications despite treatment with intravenous immunoglobulin (IVIG). These high complication rates now emphasize the need for an urgent reappraisal of IVIG as the…
Setting-up a high quality, compliant and efficient pharmacovigilance (PV) system in multi-country clinical trials can be more challenging for academic sponsors than for companies. To ensure the safety of all participants in academic studies and that the PV system fulfils all regulations, we set up a centralized PV system that allows sponsors to delegate work…
Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children – CTS Journal – Wiley Online Library Many medicines are used “off-label” in children outside the terms of the license and feasible pediatric clinical trials are a challenge to design. Conect4children (c4c) is an Innovative Medicines Initiative project to set up a…
A very successful webinar on Artificial Intelligence (AI) in paediatrics took place on the 7th of December 2022.
As of 2017 Pedmed-NL is the Dutch network to facilitate paediatric clinical trials.
conect4children is pleased to announce that the third c4c International Multi-Stakeholder Meeting (MSM) will address medical devices in paediatric type I diabetes.
Thanks to advances in neonatal care and technology, babies born as early as 23 weeks preterm survive at higher rates than ever before.
After two years of virtual meetings, as the c4c Project Leadership Team, we were pleased to see so many c4c Beneficiaries in person at the General Assembly in June in Ghent.
If you want to stay updated, visit the NEW conect4children Stichting (c4c-S) website:
Or if you are here to look at information about the c4c project, please feel free to disregard this message and keep navigating.